The drug has a haemostatic effect, has an angioprotective and proaggregant effect. Stimulates the formation of platelets and their exit from the bone marrow.
Hemostatic action is due to the activation of thromboplastin formation at the site of damage to small vessels and a decrease in the formation of prostacyclin vessels in the endothelium. This helps to increase the adhesion and aggregation of platelets, which ultimately leads to stopping or reducing bleeding.
Increases the rate of formation of the primary thrombus and strengthens its retraction, practically does not affect the level of fibrinogen and prothrombin time. Doses of more than 2-10 mg / kg do not lead to greater severity of the effect. With repeated injections, thrombus formation is intensified.
Possessing anti-hyaluronidase activity and stabilizing ascorbic acid, it prevents destruction and promotes the formation in the capillary wall of mucopolysaccharides with a large molecular weight, increases the resistance of capillaries, reduces their fragility, normalizes the permeability of the latter in pathological processes.
Reduces the yield of fluid and diapedesis of blood elements from the vascular bed, improves microcirculation.
Has no hypercoagulable properties, does not have vasoconstrictive effect.
When administered, the maximum effect is observed after 2-4 hours.